Genomic Vision to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
08 Février 2016 - 2:00PM
Business Wire
Genomic Vision (GV:EN Paris), a French molecular diagnostics
company specializing in the development of diagnostic tests for
genetic diseases and cancers based on molecular combing technology,
announced today that the Company management will be participating
at Source Capital Group’s 2016 Disruptive Growth & Healthcare
Conference taking place February 10-11, 2016 in New York City.
Chief Executive Officer Aaron Bensimon, Ph.D., will present a
corporate overview at 2:45PM Eastern time on February 10th.
The Source Conference presentation will be webcast and can be
found on the Company’s website www.genomicvision.com or at the
following hyperlink, Genomic Vision Source Conference Webcast.
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a molecular diagnostics
company specialized in the development of diagnostic tests for
genetic diseases and cancers based on molecular combing. Using this
innovative technology that allows the direct visualization of
individual DNA molecules, Genomic Vision detects quantitative and
qualitative variations in the genome that are at the origin of
numerous serious pathologies. The Company is developing a solid
portfolio of tests that notably target breast cancer and cancer of
the colon. Since 2013, the Company has marketed the CombHeliX FSHD
test for identifying a myopathy that is difficult to detect,
Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks
to a strategic alliance with Quest Diagnostics, the American leader
in diagnostic laboratory tests, and in France. Genomic Vision has
been listed on Compartment C of Euronext Paris since April
2014.
For further information, please go to www.genomicvision.com
Member of CAC® Mid & Small, CAC®
All-Tradable and EnterNext© PEA-PME 150 indexes
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160208005088/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorLHAInvestor Relations
USAnne Marie Fields, SVP,
212-838-3777afields@lhai.comorNewCapInvestor RelationsDušan
OrešanskýorStrategic CommunicationsEmmanuel Huynh+33 1 44 71 94
92gv@newcap.fr
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Goldfield Corp (American Stock Exchange): 0 recent articles
Plus d'articles sur Goldfield